EYLEA HD Trademark

Trademark Overview

On Friday, February 11, 2022, a trademark application was filed for EYLEA HD with the United States Patent and Trademark Office. The USPTO has given the EYLEA HD trademark a serial number of 97264271. The federal status of this trademark filing is REGISTERED as of Tuesday, September 3, 2024. This trademark is owned by Regeneron Pharmaceuticals, Inc.. The EYLEA HD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, ophthalmics; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions
eylea hd

General Information

Serial Number97264271
Word MarkEYLEA HD
Filing DateFriday, February 11, 2022
Status700 - REGISTERED
Status DateTuesday, September 3, 2024
Registration Number7496066
Registration DateTuesday, September 3, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2022

Trademark Statements

Goods and ServicesPharmaceutical preparations, namely, ophthalmics; pharmaceutical preparations for the treatment of ophthalmic diseases and conditions

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, February 16, 2022
Primary Code005
First Use Anywhere DateMonday, July 31, 2023
First Use In Commerce DateMonday, July 31, 2023

Trademark Owner History

Party NameRegeneron Pharmaceuticals, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591
Party NameRegeneron Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTarrytown, NY 10591

Trademark Events

Event DateEvent Description
Tuesday, February 15, 2022NEW APPLICATION ENTERED
Wednesday, February 16, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, July 14, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, July 14, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 14, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, September 26, 2022ASSIGNED TO EXAMINER
Tuesday, September 27, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 12, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 1, 2022PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 27, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, May 26, 2023SOU TEAS EXTENSION RECEIVED
Friday, May 26, 2023SOU EXTENSION 1 FILED
Friday, May 26, 2023SOU EXTENSION 1 GRANTED
Tuesday, May 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, September 1, 2023USE AMENDMENT FILED
Friday, September 1, 2023TEAS STATEMENT OF USE RECEIVED
Wednesday, September 13, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, September 13, 2023STATEMENT OF USE PROCESSING COMPLETE
Monday, February 12, 2024SU - NON-FINAL ACTION - WRITTEN
Monday, February 12, 2024NON-FINAL ACTION E-MAILED
Monday, February 12, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 23, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 25, 2024ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Thursday, July 25, 2024NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Monday, April 1, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 1, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, September 3, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 3, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED

Related Keywords

eylea pharmaceutical preparations diseases conditions ophthalmic ophthalmics namely treatment